title: Differentiation therapy for IDH1/2 mutant malignancies.
abstract: Recently discovered recurrent somatic mutations in the key metabolic enzymes IDH1 and IDH2 produce the aberrant oncometabolite 2-HG and contribute to malignant transformation of hematopoietic and glial cells. Two recent reports in Science describe the first IDH1 and IDH2 mutant-specific small-molecule inhibitors, which induce cell differentiation of myeloid leukemias and malignant gliomas.
authors.affiliation: Department of Medicine, Division of Hematology/Oncology, Weill Cornell Medical College, 1300 York Ave, New York, NY 10065, USA.
authors.forename: Francine E
authors.initials: FE
authors.lastname: Garrett-Bakelman
authors.forename: Ari M
authors.initials: AM
authors.lastname: Melnick